Figure 7. The impact of pharmacologic modulation of AMPK phosphorylation on the expressions of the incretin receptors in db/db mice.

A), B) Isolated islets from 7-week-old db/+ and db/db mice were pre-treated for 15 min with vehicle (Veh; DMSO) or an AMPK inhibitor (AMPKi; 40 µM compound C) in the presence of 2.8 mM glucose, or with vehicle (Veh; DMSO) in the presence of 11.1 mM glucose, followed by the addition of vehicle (Veh; water) for an additional 24 h. A) Total islet extracts from the isolated islets were subjected to immunoblotting for p-AMPKα (Thr¹⁷²) and AMPKα (n = 2–4). B) The GLP-1 and GIP receptor expressions were determined by real-time quantitative RT-PCR and normalized to the β actin mRNA expression level and to the vehicle-treated control samples at 2.8 mM glucose (n = 2–3). *P<0.05 and ** P<0.01.